BGB-11417-105 evaluated the safety, tolerability, and preliminary efficacy of investigational sonrotoclax with daratumumab and dexamethasone in patients with centrally confirmed t(11;14) relapsed/refractory multiple myeloma (RRMM).
This ongoing phase 1b/2 study enrolled patients with RRMM with centrally confirmed t(11;14). Part 1 enrolled patients with ≥3 prior lines of therapy (PLoT) including a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 antibody; Part 2 enrolled patients with 1-3 PLoT including a PI and IMiD (prior anti-CD38 antibody allowed with exclusions for recent use or refractoriness). Oral sonrotoclax (160, 320, or 640 mg once daily) was administered with oral/intravenous dexamethasone (40 mg once weekly) and subcutaneous daratumumab (1,800 mg per standard schedule; SDd) in 28-day cycles. Dose-limiting toxicities (DLTs) were assessed through day 28 of cycle 1. Treatment-emergent adverse events (TEAEs) were classified per MedDRA v29.0 and graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The primary endpoint was safety and tolerability; efficacy was assessed by investigators per International Myeloma Working Group criteria.
A total of 72 patients with t(11;14) RRMM received SDd (sonrotoclax 160 mg: n=5; 320 mg: n=33; 640 mg: n=34). Median age was 65 years (range, 36-91); 51% were male; 49% were White; and 19% had high-risk cytogenetics. Median PLoT was 3 (range, 1-10), with 25% having ≥4 PLoT. R-ISS stage at initial diagnosis was I in 22%, II in 42%, and III in 17% of patients. Prior anti-CD38 antibody was used in 58%, including 33% with anti-CD38-refractory disease; 56% were triple-class exposed, including 22% triple-class refractory. At data cutoff (May 20, 2026), median follow-up was 7.2 months (range, 3.3-19.1 months), and 56 patients (78%) remained on treatment.
The most common (≥20%) all-grade TEAEs were upper respiratory tract infection (36%), fatigue (31%), neutrophil count decreased (26%), diarrhea (26%), insomnia (25%), and nausea (24%). Grade 3/4 TEAEs occurred in 64%, including grade 3/4 hematologic TEAEs in 33% (most commonly neutropenia [28%]) and grade 3/4 infections and infestations in 21%. Serious adverse events occurred in 29%, most commonly pneumonia (8%). Two DLTs occurred (grade 4 neutropenia at 320 mg; grade 4 thrombocytopenia at 640 mg); the maximum tolerated dose was not reached. No investigator-assessed sonrotoclax-related TEAEs led to sonrotoclax discontinuation. No grade 5 TEAEs were reported. Two patients died during the study (progressive disease; respiratory/circulatory failure), both deemed unrelated to study treatment and occurring more than 30 days after the last dose.
Among 70 efficacy-evaluable patients, overall response rate (ORR) was 87% (95% CI, 77%-94%), very good partial response or better (≥VGPR) was 59% (95% CI, 46%-70%), and complete response or better (≥CR) was 23% (95% CI, 14%-34%). In the 320-mg cohort, ORR was 88%, ≥VGPR was 63%, and ≥CR was 22%; in the 640-mg cohort, ORR was 91%, ≥VGPR was 61%, and ≥CR was 24%. Median time to response was 1.0 month (range, 0.9-4.0 months). Median duration of response (DOR) and progression-free survival (PFS) were not reached; 12-month DOR and PFS rates were 77% (95% CI, 52%-91%) and 69% (95% CI, 46%-84%), respectively.